本瑞利珠单抗治疗血嗜酸性粒细胞≥150/μl重度哮喘的疗效与临床治愈:MIRACLE Ⅲ期研究亚组分析
基于亚洲Ⅲ期MIRACLE研究,纳入基线血嗜酸性粒细胞≥150/μl的重度哮喘患者598例,本瑞利珠单抗30 mg每48周治疗较安慰剂显著降低年化哮喘急性发作率67%,并改善肺功能、症状评分、ACQ-6及SGRQ评分;基线未用口服糖皮质激素者中本瑞利珠单抗组达到临床治愈的比例更高。
要点
- 本瑞利珠单抗降低亚洲bEOS≥150/μl重度哮喘患者AAER达67%。
- 本瑞利珠单抗改善pre-BD FEV1、TASS、ACQ-6及SGRQ评分。
- 基线未用OCS者中本瑞利珠单抗组临床治愈比例更高。
核心结论
- 本瑞利珠单抗可改善亚洲bEOS≥150/μl重度未控制哮喘患者的临床结局。
研究设计与样本
- MIRACLE为Ⅲ期临床试验,2017年9月7日至2023年1月30日从亚洲79个中心纳入12~75岁重度哮喘患者,按1∶1随机接受本瑞利珠单抗30 mg或安慰剂治疗48周。
- 共695例随机,其中598例基线bEOS≥150/μl纳入本分析(本瑞利珠单抗组301例,安慰剂组297例;年龄50.9±12.1岁;女性61.2%)。
主要发现
- 本瑞利珠单抗组AAER较安慰剂组降低67%(RR=0.33,95%CI:0.25~0.44,P<0.001)。
- 本瑞利珠单抗组pre-BD FEV1较安慰剂组改善(LSMD:0.21 L,95%CI:0.14~0.29 L,P<0.001)。
- 本瑞利珠单抗组TASS(LSMD:-0.29分,95%CI:-0.46~-0.11分,P=0.002)、ACQ-6(LSMD:-0.33分,95%CI:-0.46~-0.19分,P<0.001)及SGRQ(LSMD:-8.07分,95%CI:-11.35~-4.79分,P<0.001)改善幅度均大于安慰剂组。
- 基线无OCS使用者中(本瑞利珠单抗组277例,安慰剂组264例),24和48周时本瑞利珠单抗组达到临床治愈#1和临床治愈#2的比例均高于安慰剂组。
关键数值与推荐
- 临床治愈定义为无急性发作、FEV1较基线改善≥100 ml、ACQ-6<1.5分(临床治愈#1)或≤0.75分(临床治愈#2)。
- AAER采用负二项模型分析,其他疗效终点采用重复测量模型分析。
临床怎么用
- 对于亚洲bEOS≥150/μl的重度未控制哮喘患者,本瑞利珠单抗可显著降低急性发作并改善肺功能与生活质量。
- 基线未使用OCS的患者接受本瑞利珠单抗治疗后达到临床治愈的比例更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy of benralizumab in patients with baseline bEOS ≥150 cells/μl using data from the MIRACLE study in Asia. Methods: MIRACLE was a phase Ⅲ clinical trial. From September 7, 2017 to January 30, 2023, patients aged 12-75 years with eosinophilic severe asthma receiving medium- to high-dosage inhaled corticosteroids and long-acting β2 agonists were enrolled from 79 centres in Asia. They were randomized (1∶1) to receive either benralizumab 30 mg or placebo for 48 weeks. The endpoints included annual asthma exacerbation rate (AAER), pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV1), total asthma symptom score (TASS), St George's Respiratory Questionnaire (SGRQ) score, and the proportion of patients achieving clinical remission (defined as no asthma exacerbations, FEV1 improvement ≥100 ml, and 6-item Asthma Control Questionnaire [ACQ-6 score;≤0.75 or <1.5]; at Weeks 24 and 48) in patients with no baseline oral corticosteroid (OCS) use. Results: Of 695 patients randomized, 598 patients had baseline bEOS ≥150 cells/μl [benralizumab n=301, placebo n=297; age: (50.9±12.1) years; 61.2% were women]. In this population, benralizumab reduced the AAER by 67% [rate ratio (RR)=0.33, 95%CI: 0.25-0.44, P<0.001) and improved lung function [least squares (LS) mean difference vs. placebo: 0.21 L, 95%CI: 0.14-0.29, P<0.001]. Benralizumab achieved greater reductions in TASS (LS mean difference:-0.29, 95%CI:-0.46--0.11, P=0.002) and ACQ-6 scores (LS mean difference:-0.33, 95%CI:-0.46--0.19, P<0.001), and improved SGRQ scores (LS mean difference:-8.07, 95%CI:-11.35--4.79], P<0.001). Among patients with no baseline OCS use (benralizumab n=277; placebo n=264), a higher proportion of benralizumab-treated patients achieved clinical remission at Weeks 24 and 48 compared to the placebo-treated patients. Conclusion: These results reinforce that benralizumab can improve clinical outcomes in patients with severe, uncontrolled asthma with bEOS ≥150 cells/μl in Asia. 目的: 评估亚洲Ⅲ期MIRACLE研究中基线外周血嗜酸性粒细胞(bEOS)≥150/μl重度哮喘患者使用本瑞利珠单抗的疗效。 方法: MIRACLE研究为Ⅲ期临床试验。2017年9月7日—2023年1月30日,从亚洲79个中心纳入12~75岁接受中高剂量吸入性糖皮质激素联合长效β2受体激动剂治疗的重度哮喘患者,按1∶1随机分组接受本瑞利珠单抗30 mg或安慰剂治疗48周。研究终点包括:年化哮喘急性发作率(AAER)、支气管舒张剂前第1秒用力呼气容积(pre-BD FEV1)、哮喘症状总评分(TASS)、圣乔治呼吸问卷(SGRQ)总分,以及基线无口服糖皮质激素(OCS)使用患者中达到“临床治愈”[定义为无急性发作、FEV1 较基线改善≥100 ml、哮喘控制评分(ACQ-6)<1.5分(临床治愈#1)或≤0.75分(临床治愈#2)]的比例。AAER采用负二项模型分析,其他疗效终点采用重复测量模型分析。 结果: 在纳入的695例患者中,598例基线bEOS≥150/μl[本瑞利珠单抗组301例,安慰剂组297例;年龄(50.9±12.1)岁;女性占61.2%]。相较于安慰剂组,本瑞利珠单抗组AAER降低67%(RR=0.33,95%CI:0.25~0.44,P<0.001),pre-BD FEV1改善[最小二乘均值差(LSMD):0.21 L,95%CI:0.14~0.29 L,P<0.001];其TASS(LSMD:-0.29分,95%CI:-0.46~-0.11分,P=0.002)、ACQ-6(LSMD:-0.33分,95%CI:-0.46~-0.19分,P<0.001)及 SGRQ(LSMD:-8.07分,95%CI:-11.35~-4.79分,P<0.001)改善幅度均大于安慰剂组。在基线无OCS使用者中(本瑞利珠单抗组277例,安慰剂组264例),24和 48周时本瑞利珠单抗组达到“临床治愈#1”和“临床治愈#2”的比例均高于安慰剂组。 结论: 本瑞利珠单抗治疗可改善亚洲bEOS≥150/μl重度未控制哮喘患者的临床结局。.
引用
- Lai, Wu, Luo, et al. [Efficacy and clinical remission in patients with severe asthma and blood eosinophil counts ≥150 cells/μl treated with benralizumab: a sub-analysis of the Phase 3 MIRACLE study]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 41073307. doi:10.3760/cma.j.cn112147-20250416-00210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。